oxybutynin has been researched along with Day Blindness in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Excerpt | Relevance | Reference |
---|---|---|
"All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit." | 1.48 | Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. ( Hsiao, SM; Kuo, HC; Lin, HH, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hsiao, SM | 1 |
Lin, HH | 1 |
Kuo, HC | 1 |
Sand, PK | 1 |
1 review available for oxybutynin and Day Blindness
Article | Year |
---|---|
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; H | 2004 |
1 other study available for oxybutynin and Day Blindness
Article | Year |
---|---|
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Midd | 2018 |